Clinical Trial: Clinical Trial of IL - 22BP Safety, Tolerability, and Antitumor Activity in Refractory Solid Tumors.
Study Status: COMPLETED
Recruit Status: COMPLETED
Condition:
Refractory Malignant Solid Tumors
mRNA Vaccine
Interleukin
Study Type: INTERVENTIONAL
Official Title: A Clinical Trial Evaluating the Safety, Tolerability, and Preliminary Antitumor Activity of IL - 22BP in Refractory Malignant Solid Tumors.
Brief Summary:
This study aims to investigate the safety and efficacy of the IL-22BP in patients with refractory malignant solid tumors.
Read more